Table 1 Characteristics of the randomized placebo-controlled trials considered for the guideline in episodic migraine
Study | Study phase | Treatment regimen | Duration of treatment | Participants (n) | Women (%) | Age range (years) | Monthly migraine days (range) | Preventive treatment (% using) | Exclusion by preventive failure (n. of drugs/ categories) |
|---|---|---|---|---|---|---|---|---|---|
Eptinezumab | |||||||||
 Dodick, 2014 [32] | II | 1000 mg quarterly ev | 3 months | 174 | 80–83 | 18–55 | 5–14 | Not Allowed | – |
Erenumab | |||||||||
 Sun, 2016 [44] | II | 70 mg monthly sc | 3 months | 483 | 77–83 | 18–60 | 4–14 | Not allowed | > 2 |
 STRIVE [36] | III | 70 mg monthly sc 140 mg monthly sc | 6 months | 955 | 85–86 | 18–65 | 4–14 | 2–3 | > 2 |
 ARISE [35] | III | 70 mg monthly sc | 3 months | 577 | 85–86 | 18–65 | 4–14 | 6–7 | > 2 |
Fremanezumab | |||||||||
 Bigal, 2015 [27] | II | 225 mg monthly sc 675 mg monthly sc | 3 months | 297 | 85–91 | 18–65 | 8–14 | 27–34 | > 2 |
 HALO EM [34] | III | 225 mg monthly sc 675 mg quarterly sc | 3 months | 875 | 84–86 | 18–70 | 6–14 | 20–21 | ≥2 |
Galcanezumab | |||||||||
 Dodick, 2014 [33] | II | 150 mg every two weeks sc | 3 months | 218 | 82–87 | 18–65 | 4–14 | Not Allowed | > 2 |
EVOLVE-2 [42] | II | 120 mg monthly sc 300 mg monthly sc | 3 months | 410 | 80–85 | 18–65 | 4–14 | NR | > 2 |
EVOLVE-1 [43] | III | 120 mg monthly sc (240 mg ld) 240 mg monthly sc | 6 months | 858 | 83–85 | 18–65 | 4–14 | Not allowed | > 2 |